While the maintenance of a Buy rating suggests continued confidence in Revance Therapeutics' fundamentals, the reduction in price target could indicate a reassessment of the company's near-term growth prospects or market conditions. This mixed signal might lead to short-term uncertainty among investors, potentially causing minor fluctuations in the stock price.